Expression of protein tyrosine kinase 6 (PTK6) in nonsmall cell lung cancer and their clinical and prognostic significance

Chao Zhao1,*
Yan Chen2,*
Weiwei Zhang2,*
Jianrong Zhang2
Yulian Xu2
Wenjie Li2
Sunxiao Chen3
Anmei Deng2

1Department of Laboratory Diagnostic, the 89th Hospital, Weifang, Shandong, People’s Republic of China; 2Department of Laboratory Diagnostic, Changhai Hospital, Second Military Medical University, Shanghai, People’s Republic of China; 3Changzheng Hospital, Second Military Medical University, Shanghai, People’s Republic of China
*These authors contributed equally to this work

Aim: The aim of the study was to validate the expression of protein tyrosine kinase 6 (PTK6) in nonsmall cell lung cancer (NSCLC), and to evaluate its clinicopathological and prognostic significance.

Methods: We first conducted a meta-analysis on the mRNA profiling data sets of NSCLC in the Oncomine database. Then, one of the most significantly upregulated tyrosine kinase targets, PTK6, was further validated by immunohistochemistry in 104 primary NSCLC tumors. Furthermore, the association between PTK6 expression, the clinical parameters, and overall survival was further analyzed.

Results: Using the Oncomine database, we identified a list of tyrosine kinase genes related to NSCLC, among which PTK6 was the second most overexpressed gene (median rank = 915, \( P = 2.9 \times 10^{-5} \)). We further confirmed that NSCLC tumors had a higher expression level of PTK6 than normal pulmonary tissues. Moreover, high PTK6 expression correlated positively with shorter overall survival time, but not with other clinicopathological characteristics. In the multivariate Cox regression model, high PTK6 expression was demonstrated to be an independent prognostic factor for NSCLC patients.

Conclusion: Our results validated that PTK6 was found to be overexpressed in a proportion of NSCLC samples, and was associated with a poor prognosis, suggesting that this subgroup of NSCLC patients might benefit from PTK6 inhibitors in the future.

Keywords: nonsmall cell lung cancer, tyrosine kinase, PTK6, target, prognosis

Introduction

Lung cancer ranks among the leading causes of cancer death globally. Mortality related to this malignant disease has risen by 465% during the last 30 years in People’s Republic of China.1 Nonsmall cell lung carcinoma (NSCLC) accounts for approximately 85% of all lung cancer cases. Even among those who have received standard treatments including surgical resection, traditional chemotherapy, radiation therapy, and molecular targeted therapy, a significant proportion of NSCLC patients eventually develop resistance to chemotherapy and recurrence. Therefore, there is an urgent need to discover novel cancer-specific molecular targets and signaling pathways to develop new therapeutic strategies against this devastating malignancy.

Tyrosine kinases, being capable of phosphorylating specific target protein substrates, are involved in the modulation of multiple growth factor signaling during cancer progression.2 In recent years, a list of tyrosine kinase inhibitors has been approved, while others are in clinical trials for NSCLC patients.3,4 Therefore, identifying new
tyrosine kinases related to NSCLC would be of important significance in developing novel treatment strategies for this cancer.

In this study, we first performed a meta-analysis on the gene expression profiling data sets of NSCLC specimens from the Oncomine database (Compendia Bioscience, Inc, Ann Arbor, MI, USA), and identified a tyrosine kinase, protein tyrosine kinase 6 (PTK6), was specifically upregulated in NSCLC when compared to normal lung tissues, which might be a novel biomarker and potential therapeutic target for NSCLC. We further validated its expression in NSCLC samples and evaluated its clinicopathological and prognostic significance.

Materials and methods

Data mining

The Oncomine cancer microarray database was used to analyze the mRNA expression profiles of NSCLC tissues relative to their normal controls. Eleven publicly available datasets of gene expression profiles of were chosen in this study. The data mining strategy is based on a published methodology established by Oncomine. First, significantly upregulated genes in cancer samples compared with the normal tissue counterpart (greater than twofold, \( P < 0.05 \)) were selected. Then, concept filters in the Oncomine database were used to identify known tyrosine kinases differentially expressed in NSCLC.

Samples

 Archived formalin-fixed paraffin-embedded NSCLC samples with corresponding adjacent nontumor tissues undergoing surgical resection were obtained from the 89th Hospital, Changhai Hospital, and from the Changzheng Hospital of People’s Republic of China between January 2006 and December 2008. General schemes for treatment choice in the sampled NSCLC patients were based on the National Comprehensive Cancer Network NSCLC Clinical Practice Guidelines (Chinese version). Overall survival was calculated from the date of surgery until the date of death or last follow-up. None of the patients had received neoadjuvant chemotherapy, radiation therapy, or immunotherapy. Ethics approval to start this study was obtained from the local Human Research Ethics Committees.

Immunohistochemistry

 The immunostaining was performed according to standard SP methods according to the manufacturer’s protocol (Zymed®, Life Technologies, Carlsbad, CA, USA). Antigen retrieval was done by a combination of heat and pressure in sodium citrate buffer. Immunostaining was detected with a rabbit polyclonal antibody against PTK6 (Santa Cruz Biotechnology, Inc, Dallas, TX, USA). Detection was performed using diaminobenzidine as the chromogen. Nonspecific rabbit immunoglobulin G was used as negative control.

The immunostaining levels of PTK6 protein expression were assessed using a semiquantitative staining index method, as described previously with minor modifications. The staining intensity results were graded to a four-scale (0 = no staining; 1 = staining obvious only at × 400; 2 = staining obvious at × 100 but not × 40) and 3 = staining obvious at × 40), while the percentages of positive cells were scored into four scales (0 = 0% positive cells; 1 = 1%–33% positive cells; 2 = 34%–66% positive cells; and 3 = 67%–100% positive cells). A staining index ranging from 0 to 9 was generated by multiplying staining intensity and the percentage of positive cells for each sample. The median staining index value was set as a cut-point to delineate PTK6-low and PTK6-high subgroups.

Statistics

The difference in clinicopathological characteristics between PTK6-low and PTK6-high subgroups was compared using the Chi-square test. Overall survival curves were estimated using the Kaplan–Meier method and evaluated using the Log-Rank test. Multivariate analysis on clinicopathological variables and PTK6 expression levels was performed using the Cox proportional hazard regression model. Statistical analyses were performed using the Statistical Package for the Social Sciences 16.0 (SPSS; IBM Corporation, Armonk, NY, USA), and a \( P \)-value less than 0.05 was considered statistically significant.

Results

We first queried the Oncomine database to systematically compare the relative gene expression levels between NSCLC and normal pulmonary samples, then upregulating genes belonging to tyrosine kinase targets were further filtered out using a “tyrosine protein kinase, active site – InterPro Protein Domains and Families” concept. The top 20 upregulated tyrosine kinase genes in NSCLC are listed in Figure 1. In the meta-analysis, discoidin domain receptor 1 (DDR1) was the lowest ranked gene (median rank = 683) among all of the tyrosine kinase genes with a \( P \)-value of 3.05 \( \times \)10\(^{-4}\). Next on the list, with a median rank of 915 and a \( P \)-value of 2.96 \( \times \)10\(^{-3}\), was PTK6. Our bioinformatics analysis strongly suggested that
PTK6 genes were closely associated with NSCLC, and might be a potential tyrosine kinase target for NSCLC.

We further applied a validation study of PTK6 expression in a panel of clinical samples. As for the staining pattern, the positive staining reaction for PTK6 in normal and cancerous lung tissue cells was observed in the cytoplasm, and in a combination of the nucleus and cytoplasm. Compared with normal lung tissues, NSCLC tissues had a significantly higher staining index of PTK6. For NSCLC tissues, the median staining index of 6 was set as the cut-point to delineate PTK6-low and PTK6-high subgroups. Representative immunostaining images were seen in Figure 2. The associations between PTK6 expression and clinicopathological features of NSCLC are shown in Table 1. No significant association was observed between PTK6 expression with the clinicopathological traits observed in this study. Furthermore, we also found no significant correlation between PTK6 expression with another tyrosine kinase target epidermal growth factor receptor (EGFR) mutation status.

Survival curves were plotted using the Kaplan–Meier method as seen in Figure 3. The results indicated that the patients with a high PTK6 expression had a significantly shorter survival time, compared with those with low expression. High expression of PTK6 protein showed a statistically significant association with survival in univariate analysis (hazard ratio = 2.031, 95% confidence interval = 1.099–3.755, P = 0.024 by Log-Rank test). All the NSCLC clinical and pathological factors together with PTK6 expression status were included in a multivariate Cox regression model (Table 2). Our data demonstrated that high PTK6 expression retained a significant and independent prognostic factor for NSCLC patients (hazard ratio = 2.219, 95% confidence interval = 1.156–4.263, P = 0.017 by Log-Rank test).

**Discussion**

By meta-analysis on the Oncomine database, we screened and identified a list of upregulated tyrosine kinase genes in NSCLC, including some already confirmed therapeutic targets.
targets such as EGFR. The first ranking tyrosine kinase gene DDR1 has been demonstrated to contribute to the progression and poor prognosis of NSCLC in previous studies, and could serve as a potential therapeutic target.\textsuperscript{7,8} We further selected one of the top genes, PTK6, for further verification. This tyrosine kinase was chosen for the following reasons: firstly, in the gene expression microarray meta-analysis, PTK6 was the second ranked gene among all of the tyrosine kinase genes, and was shown to be significantly elevated in NSCLC tumors; secondly, the expression of PTK6 in NSCLC has not been widely investigated, and specifically its prognostic value has not been reported; thirdly, commercial antibodies for PTK6 immunohistochemistry are available.

We further evaluated the clinicopathological and prognostic significance of PTK6 expression in NSCLC tumors. Our immunostaining results validated that high expression of PTK6 was detectable in NSCLC tumor samples and was significantly correlated with decreased overall survival. Through multivariate analysis, high expression of PTK6 was shown to be an independent prognostic biomarker for poor overall survival. As far as we know, this is the first report of the prognostic significance of PTK6 expression in clinical NSCLC tissue samples. However, different from the previous study,\textsuperscript{9} no significant association with tumor size, lymph node metastasis status, and TNM stage were found in this study. We think the difference between data from the current study and previous report might be a result of the different evaluation criteria of the immunohistochemistry staining adopted. Our findings suggest that high-PTK6 expressed NSCLC tumors could represent a distinct subgroup with more aggressive phenotypes and a poor prognosis, which might benefit from more intensive and targeted treatments including PTK-specific inhibitors.

PTK6 (also known as breast tumor kinase) is a nonreceptor tyrosine kinase, which has been originally cloned from human melanocytes and a metastatic breast tumor sample.\textsuperscript{10,11} High expression of PTK has been found in several cancer types, including breast cancer, melanoma, and colon cancer.\textsuperscript{12,13} Accumulating evidence indicated that PTK6 played an important regulatory role as a proto-oncogene in malignant settings, and was involved directly in the processes of proliferation, migration, and invasion in cancer cells.\textsuperscript{14} Harvey et al\textsuperscript{15} found that the proliferation of breast carcinoma cells was efficiently suppressed by specifically downregulated PTK6 protein levels using RNA interference. PTK6 has been demonstrated to interact with the ErbB family members EGFR, ErbR2, ErbR3, ErbR4, and enhanced

| Table 1 Association between PTK6 expression and clinicopathological characteristics of the patients with NSCLC |
|----------------------------------|---|---|---|
| N | PTK6 | P-value |
|---|---|---|
| Low expression (n = 53) | High expression (n = 51) |
| Age (years) | | |
| <60 | 31 | 19 | 12 | 0.734 |
| ≥60 | 73 | 34 | 39 | |
| Gender | | | |
| Male | 79 | 41 | 38 | 0.170 |
| Female | 25 | 12 | 13 | |
| Smoking status | | | |
| Nonsmoker | 32 | 17 | 15 | 0.769 |
| Smoker | 72 | 36 | 36 | |
| Pathological type | | | |
| Squamous cell carcinoma | 51 | 30 | 21 | 0.116 |
| Adenocarcinoma | 53 | 23 | 30 | |
| Tumor size | | | |
| T1–T2 | 89 | 47 | 42 | 0.359 |
| T3 | 15 | 6 | 9 | |
| Lymph node status | | | |
| Negative | 56 | 28 | 28 | 0.832 |
| Positive | 48 | 25 | 23 | |
| Tumor grade | | | |
| G1–G2 | 65 | 33 | 32 | 0.96 |
| G3 | 39 | 20 | 19 | |
| TNM stage | | | |
| I–II | 72 | 36 | 36 | 0.969 |
| III–IV | 32 | 17 | 15 | |
| EGFR mutation | | | |
| Absent | 85 | 44 | 41 | 0.729 |
| Present | 19 | 9 | 10 | |

Abbreviations: PTK6, protein tyrosine kinase 6; NSCLC, nonsmall cell lung cancer; N, number; EGFR, epidermal growth factor receptor.
EFG-induced proliferation and ERK1/2 activation.16–18 It has also been reported that PTK6 could also activate the PI3k/Akt and STAT pathway.17 Moreover, potential PTK substrates also include a variety of several signaling molecules such as p190RhoGAP, paxillin, Akt, and KAP3A in most human cancer cells.19–21 Therefore, considering the overexpression of PTK6 in NSCLC, and its positive association with a poor prognosis, we proposed that specific inhibition of PTK6 kinase activity may provide a potentially novel approach to treat patients with NSCLC in the future. In particular, recently, Zeng et al22 discovered imidazo[1,2-a]pyrazin-8-amins as potent PTK6 kinase inhibitors. The utility of these small molecular PTK6 inhibitors in NSCLC treatment deserves further investigation.

In conclusion, in this study, by meta-analysis on the gene microarray data of NSCLC, we screened and validated a novel tyrosine kinase, PTK6, overexpressed in NSCLC tumors, which was correlated positively to shorter survival. Our findings are, however, preliminary and require other validations on a larger and independent group of NSCLC patients. We also suggest that the exact mechanisms of PTK6 during the malignant progression of NSCLC and its relationship with other confirmed NSCLC tyrosine kinase targets such as ALK deserves further investigation in the future.

Acknowledgments

This research was supported by grants from the National Science Foundation of People’s Republic of China (81273282, 30972730), 973 Foundation (2013CB531606), Shanghai Municipal Commission for Science and Technology (11 JC1410902), and Changhi Hospital (CH125530300).

Disclosure

The authors report no conflicts of interest in this work.

Table 2 Univariate and multivariate analysis for prognosis

| Variable                  | Univariate survival analyses | Multivariate survival analyses |
|---------------------------|------------------------------|-------------------------------|
|                           | HR for death (95% CI)        | Adjusted HR for death (95% CI) |
| Age                       | 1.411 (0.711–2.801)         | 1.238 (0.594–2.580)          |
| Gender                    | 0.882 (0.434–1.790)         | 0.645 (0.208–2.001)         |
| Smoking status            | 0.959 (0.506–1.817)         | 0.436 (0.163–1.165)         |
| Pathological type         | 1.267 (0.696–2.308)         | 1.468 (0.691–3.121)         |
| Tumor size                | 1.490 (0.690–3.218)         | 0.582 (0.224–1.512)         |
| Lymph node status         | 3.092 (1.617–5.911)         | 3.060 (1.284–7.290)         |
| Tumor grade               | 1.136 (0.619–2.081)         | 1.207 (0.629–2.313)         |
| TNM stage                 | 2.324 (1.269–4.255)         | 1.151 (0.465–2.848)         |
| EGFGR mutation            | 3.392 (1.760–6.536)         | 3.172 (1.548–6.501)         |
| PTK6 expression           | 2.031 (1.099–3.755)         | 2.219 (1.156–4.263)         |

Abbreviations: HR, hazard ratios; CI, confidence intervals; EGFR, epidermal growth factor receptor; PTK6, protein tyrosine kinase 6.

References

1. Wen C, Dehnel T. People’s Republic of China wrestles with lung cancer. Lancet Oncol. 2011;12(1):15.
2. Arora A, Schollar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther. 2005;315(3):971–979.
3. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol. 2005;23(11):2556–2568.
4. Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev. 2004;30(3):255–268.
5. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9(2):166–180.
6. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res. 2002;8(9):2912–2923.
7. Ford CE, Lau SK, Zhu CQ, Andersson T, Tsao MS, Vogel VF. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Breast Cancer Res Treat. 2007;96(5):808–814.
8. Yang SH, Baek HA, Lee HJ, et al. Discoidin domain receptor 1 is associated with poor prognosis of non-small cell lung carcinomas. Oncol Rep. 2010;24(2):311–319.
9. Fan C, Zhao Y, Liu D, Zhang X, Wang E. Detection of Brk expression in non-small cell lung cancer: clinicopathological relevance. Tumour Biol. 2011;32(5):873–880.
10. Mitchell PJ, Barker KT, Martinodale JE, et al. Cloning and characterisation of cDNAs encoding a novel non-receptor tyrosine kinase, brk, expressed in human breast tumours. Oncogene. 1994;9(8):2383–2390.
11. Lee ST, Strunk KM, Spritz RA. A survey of protein tyrosine kinase mRNAs expressed in normal human melanocytes. Oncogene. 1993;8(12):3403–3410.
12. Barker KT, Jackson LE, Crompton MR. BRK tyrosine kinase expression in a high proportion of human breast carcinomas. Oncogene. 1997;15(7):799–805.
13. Llor X, Serfas MS, Bie W, et al. BRK/Sik expression in the gastrointestinal tract and in colon tumors. Clin Cancer Res. 1999;5(7):1767–1777.
14. Harvey AJ, Crompton MR. The Brk protein tyrosine kinase as a therapeutic target in cancer: opportunities and challenges. Anticancer Drugs. 2004;15(2):107–111.
15. Harvey AJ, Crompton MR. Use of RNA interference to validate Brk as a novel therapeutic target in breast cancer: Brk promotes breast carcinoma cell proliferation. Oncogene. 2003;22(32):5006–5010.
16. Xiang B, Chatt K, Qiu H, et al. Brk is coamplified with ErbB2 to promote proliferation in breast cancer. Proc Natl Acad Sci U S A. 2008;105(34):12463–12468.
17. Kamalati T, Jolin HE, Fry MJ, Crompton MR. Expression of the BRK tyrosine kinase in mammary epithelial cells enhances the coupling of EGF signalling to PI 3-kinase and Akt, via erbB3 phosphorylation. *Oncogene*. 2000;19(48):5471–5476.

18. Aubele M, Walch AK, Ludyg A, et al. Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients. *Br J Cancer*. 2008;99(7):1089–1095.

19. Chen HY, Shen CH, Tsai YT, Lin FC, Huang YP, Chen RH. Brk activates ral and promotes cell migration and invasion by phosphorylating paxillin. *Mol Cell Biol*. 2004;24(24):10558–10572.

20. Ikeda O, Miyasaka Y, Sekine Y, et al. STAP-2 is phosphorylated at tyrosine-250 by Brk and modulates Brk-mediated STAT3 activation. *Biochem Biophys Res Commun*. 2009;384(1):71–75.

21. Qiu H, Zappacosta F, Su W, Annan RS, Miller WT. Interaction between Brk kinase and insulin receptor substrate-4. *Oncogene*. 2005;24(36):5656–5664.

22. Zeng H, Belanger DB, Curran PJ, et al. Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors. *Bioorg Med Chem Lett*. 2011;21(19):5870–5875.

23. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. *Nat Med*. 2002;8(8):816–824.

24. Pedersen N, Mortensen S, Sorensen SB, et al. Transcriptional gene expression profiling of small cell lung cancer cells. *Cancer Res*. 2003;63(8):1943–1953.

25. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. *Proc Natl Acad Sci U S A*. 2001;98(24):13784–13789.

26. Hou J, Aerts J, den Hamer B, et al. Gene expression-based classification of non-small cell lung carcinomas and survival prediction. *PLoS One*. 2010;5(4):e10312.

27. Landi MT, Dracheva T, Rotunno M, et al. Gene expression signature of cigarette smoking and its role in lung adenocarcinoma development and survival. *PLoS One*. 2008;3(2):e1651.

28. Stearman RS, Dwyer-Nield L, Zerbe L, et al. Analysis of orthologous gene expression between human pulmonary adenocarcinoma and a carcinogen-induced murine model. *Am J Pathol*. 2005;167(6):1763–1775.

29. Su LJ, Chang CW, Wu YC, et al. Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. *BMC Genomics*. 2007;8:140.

30. Wachi S, Yoneda K, Wu R. Interactome-transcriptome analysis reveals the high centrality of genes differentially expressed in lung cancer tissues. *Bioinformatics*. 2005;21(23):4205–4208.

31. Yamagata N, Shyr Y, Yanagisawa K, et al. A training-testing approach to the molecular classification of resected non-small cell lung cancer. *Clin Cancer Res*. 2003;9(13):4695–4704.